Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies

Cancer Chemotherapy and Pharmacology

Volumn 75, Issue 1, 2015, Pages 111-121

  Marostica, Eleonora ^a   Sukbuntherng, Juthamas ^b   Loury, David ^b   De Jong, Jan ^c   De Trixhe, Xavier Woot ^c   Vermeulen, An ^c   De Nicolao, Giuseppe ^a   O'Brien, Susan ^d   Byrd, John C ^e   Advani, Ranjana ^f   McGreivy, Jesse ^b   Poggesi, Italo ^c  

^a UNIVERSITY OF PAVIA   (Italy)

^b PHARMACYCLICS INC   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f STANFORD CANCER INSTITUTE   (United States)

Author keywords

ADME; Covariate analysis; Nonlinear mixed effects model; Phase I II

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; CREATININE; IBRUTINIB; LACTATE DEHYDROGENASE; AGAMMAGLOBULINAEMIA TYROSINE KINASE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER PATIENT; CAUCASIAN; CHRONIC LYMPHATIC LEUKEMIA; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DOSE CALCULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; FEMALE; HUMAN; LIPID DIET; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; OBSERVATIONAL STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VOLUME OF DISTRIBUTION; VOLUME OF DISTRIBUTION AT STEADY-STATE; ADULT; AGED; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; FOOD DRUG INTERACTION; HALF LIFE TIME; INTESTINE ABSORPTION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, MANTLE-CELL; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; COHORT STUDIES; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOOD-DRUG INTERACTIONS; HALF-LIFE; HUMANS; INTESTINAL ABSORPTION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES;

EID: 84925229632     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2617-3     Document Type: Article

References (23)

1. Byrd JC, Fuman RR, Coutre S.E., Flinn IW, Burger JA, Blum KA et al (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369:32-42
2. Wang ML, Rule S, Martin P., Goy A, Auer R, Kahl BS et al (2013) Targeting BTK with ibrutinib in relapsed or refractory mantlecell lymphoma. N Engl J Med 369:507-516
3. Woyach JA, Johnson AJ, Byrd J.C. (2012) The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 120:1175-1184
4. Wiestner A (2013) Targeting B-cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol 31:128-130
5. Herman SEM, Gordon AL, Hertlein E, Ramanunni A., Zhang X, Jaglowski S et al (2011) Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-3276. Blood 117:6287-6296
6. Advani RH, Buggy JJ, Sharman J.P., Smith SM, Boyd TE, Grant B et al (2013) Bruton tyrosine kinase inhibitor Ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 31:88-94
7. Honigberg LA, Smith AM, Sirisawad M, Verner E., Loury D, Chang B et al (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 107:13075-13080
8. Poggesi I, Sardu ML, Marostica E, Sukbuntherng J., Chang B Y, de Jong J, Woot de Trixhe X, Vermeulen A, De Nicolao G, O'Brien SM, Byrd JC, Advani RH, James DF, Deraedt W, Beaupre D, Wang M (2014). Population pharmacokinetic-pharmacodynamic (PKPD) modeling of ibrutinib in patients with B-Cell malignancies. Accepted for AACR meeting "Hematological malignancies: Translating discoveries in novel therapies" September 20-23, 2014 Sheraton Philadelphia Downtown Philadelphia, PA, USA
9. Beal S, Sheiner LB, Boeckmann A, Bauer R.J., NONMEM (2009) User's guides. Icon Development Solutions, Ellicott City
10. Ette Ene I., Williams Paul J (2007) Pharmacometrics: the science of quantitative pharmacology. Wiley-Interscience, New York
11. Oberg A, Davidian M. (2000) Estimating data transformations in nonlinear mixed effects models. Biometrics 56:65-72
12. Bonate PL (2011) Pharmacokinetic-pharmacodynamic modeling and simulation, 2nd edn. Springer, New York
13. Bonate PL (1999) The effect of collinearity on parameter estimates in nonlinear mixed effect modeling. Pharm Res 16:709-717
14. Wahlby U, Jonsson EN, Karlsson M.O. (2002) Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci 4(4):27
15. R Development Core Team (2012) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, (URL http://www.R-project.org)
16. DIDB: drug interaction DataBase: University of Washington (www.druginteractioninfo.org), Accessed 20 March 2013
17. Xu SX, Dunne A, Kimko H., Nandy P, Vermeulen A. (2011) Impact of low percentage of data below the quantification limit on parameter estimates of pharmacokinetic models. J Pharma-cokinet Pharmacodyn 38:423-432
18. Anderson BJ, Holford NHG (2008) Mechanism-based concepts of size and maturity. Annu Rev Pharmacol Toxicol 48:303-332
19. Jong de J., Sukbuntherng J, Skee D., Murphy J, O'Brien S, Byrd JC, et a.l. (2014) Evaluation of the pharmacokinetics and food effect of oral ibrutinib in healthy subjects and chronic lymphocytic leukemia patients. AACR annual meeting. Abstract #4637: April 5-9
20. Imbruvica prescribing information (2013) http://www.imbruvica.com/downloads/Prescribing-Information.pdf. Accessed 24 February 2013
21. Sukbuntherng J, Jong de J, Skee D, Pak Y., Fardis M, O'Brien S et al (2014) Pharmacokinetics and safety of ibrutinib with concomitant use of CYP3A inhibitors in patients with B-cell malignancies. ACCP annual meeting
22. Hsu A, Granneman GR, Witt G, Locke C., Denissen J, Molla A et al (1997) Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 41:898-905
23. Montgomery DC, Peck E.A. (1982) Introduction to linear regression analysis. Wiley, London, p 277